| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
692.40(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.17 - $24.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
57,878 |
165,115 |
165,115 |
195,533 |
| Total Sell Value |
$1,217,382 |
$3,085,988 |
$3,085,988 |
$4,069,195 |
| Total People Sold |
2 |
2 |
2 |
3 |
| Total Sell Transactions |
4 |
7 |
7 |
14 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simpson Curran |
Chief Oper. & Tech. Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,800 |
17,748 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
11,000 |
|
- |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,800 |
16,372 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
40,984 |
281,984 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
11,600 |
19,043 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,400 |
145,424 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-28 |
4 |
AS |
$48.47 |
$316,334 |
D/D |
(6,500) |
241,000 |
|
-24% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-28 |
4 |
OE |
$0.85 |
$5,525 |
D/D |
6,500 |
247,500 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-12-24 |
4 |
AS |
$50.00 |
$168,800 |
D/D |
(3,376) |
133,024 |
|
-29% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-23 |
4 |
AS |
$50.00 |
$225,000 |
D/D |
(4,500) |
241,000 |
|
-33% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-23 |
4 |
OE |
$0.85 |
$3,825 |
D/D |
4,500 |
245,500 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-12-23 |
4 |
AS |
$50.01 |
$1,056,411 |
D/D |
(21,124) |
136,400 |
|
-33% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-16 |
4 |
AS |
$45.00 |
$675,000 |
D/D |
(15,000) |
241,000 |
|
-17% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-16 |
4 |
OE |
$0.85 |
$12,750 |
D/D |
15,000 |
256,000 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-12-11 |
4 |
AS |
$40.17 |
$599,176 |
D/D |
(14,916) |
157,524 |
|
-14% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-10 |
4 |
AS |
$40.00 |
$180,000 |
D/D |
(4,500) |
241,000 |
|
-11% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2020-12-10 |
4 |
OE |
$0.85 |
$3,825 |
D/D |
4,500 |
245,500 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-12-10 |
4 |
AS |
$40.06 |
$904,715 |
D/D |
(22,584) |
172,440 |
|
-11% |
|
| Fox Allan M. |
Director |
– • – |
2020-08-06 |
4 |
GA |
$0.00 |
$0 |
I/I |
90,000 |
315,000 |
|
- |
|
| Fox Allan M. |
Director |
– • – |
2020-08-06 |
4 |
GD |
$0.00 |
$0 |
I/I |
90,000 |
1,324,110 |
|
- |
|
| Fox Allan M. |
Director |
– • – |
2020-07-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
225,000 |
225,000 |
|
- |
|
| Fox Allan M. |
Director |
– • – |
2020-07-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
225,000 |
1,414,110 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-07-15 |
4 |
AS |
$40.10 |
$599,495 |
D/D |
(14,950) |
195,024 |
|
-11% |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-07-15 |
4 |
OE |
$13.09 |
$42,660 |
D/D |
3,259 |
209,974 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2020-06-30 |
4 |
A |
$31.31 |
$20,067 |
D/D |
641 |
7,443 |
|
- |
|
404 Records found
|
|
Page 6 of 17 |
|
|
0.30 (1.94%) 
